Cargando…

Structural Characteristics of Heparin Binding to SARS-CoV-2 Spike Protein RBD of Omicron Sub-Lineages BA.2.12.1, BA.4 and BA.5

The now prevalent Omicron variant and its subvariants/sub-lineages have led to a significant increase in COVID-19 cases and raised serious concerns about increased risk of infectivity, immune evasion, and reinfection. Heparan sulfate (HS), located on the surface of host cells, plays an important rol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Deling, Bu, Changkai, He, Peng, Song, Yuefan, Dordick, Jonathan S., Linhardt, Robert J., Chi, Lianli, Zhang, Fuming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788508/ https://www.ncbi.nlm.nih.gov/pubmed/36560700 http://dx.doi.org/10.3390/v14122696

Ejemplares similares

A booster of Delta-Omicron RBD-dimer protein subunit vaccine augments sera neutralization of Omicron sub-variants BA.1/BA.2/BA.2.12.1/BA.4/BA.5
por: Duan, Minrun, et al.
Publicado: (2023)

Omicron Waves in Argentina: Dynamics of SARS-CoV-2 Lineages BA.1, BA.2 and the Emerging BA.2.12.1 and BA.4/BA.5
por: Torres, Carolina, et al.
Publicado: (2023)

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
por: Cao, Yunlong, et al.
Publicado: (2022)

Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5
por: Muik, Alexander, et al.
Publicado: (2022)

Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5
por: Arora, Prerna, et al.
Publicado: (2022)

Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5
por: Fang, Zhenhao, et al.
Publicado: (2022)

Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants
por: Takashita, Emi, et al.
Publicado: (2022)

Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5
por: Hachmann, Nicole P., et al.
Publicado: (2022)

Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5
por: Wang, Qian, et al.
Publicado: (2022)

Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice
por: Muik, Alexander, et al.
Publicado: (2022)

Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
por: Tseng, Hung Fu, et al.
Publicado: (2023)

Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants
por: Qu, Panke, et al.
Publicado: (2022)

Humoral responses against SARS-CoV-2 Omicron BA.2.11, BA.2.12.1 and BA.2.13 from vaccine and BA.1 serum
por: Huo, Jiandong, et al.
Publicado: (2022)

Estimating the serial intervals of SARS‐CoV‐2 Omicron BA.4, BA.5, and BA.2.12.1 variants in Hong Kong
por: Guo, Zihao, et al.
Publicado: (2023)

Impact of mutations defining SARS-CoV-2 Omicron subvariants BA.2.12.1 and BA.4/5 on Spike function and neutralization
por: Pastorio, Chiara, et al.
Publicado: (2023)

Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages
por: Ai, Jingwen, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2
por: Evans, John P., et al.
Publicado: (2022)

Outcomes of Omicron sub-lineages BA.1.1 and BA.2 infection compared with the sub-lineage BA.1 infection in emergency departments' patients
por: Bouzid, Donia, et al.
Publicado: (2023)

Interactions of heparin with key glycoproteins of human respiratory syncytial virus
por: Shi, Deling, et al.
Publicado: (2023)

Omicron Sub-Lineages (BA.1.1.529 + BA.*) Current Status in Ecuador
por: Carrazco-Montalvo, Andrés, et al.
Publicado: (2022)

COVID-19 rebound after Paxlovid treatment during Omicron BA.5 vs BA.2.12.1 subvariant predominance period
por: Wang, Lindsey, et al.
Publicado: (2022)

Interactions between heparin and SARS-CoV-2 spike glycoprotein RBD from omicron and other variants
por: Gelbach, Adrianne L., et al.
Publicado: (2022)

Modeling the Prediction on the Efficacy of a Homologous Third Dose of CoronaVac Against SARS-CoV-2 Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 — China, 2020–2021
por: Chen, Xinhua, et al.
Publicado: (2023)

Partial ORF1ab Gene Target Failure with Omicron BA.2.12.1
por: Rodino, Kyle G., et al.
Publicado: (2022)

Lack of effectiveness of Bebtelovimab monoclonal antibody among high-risk patients with SARS-Cov-2 Omicron during BA.2, BA.2.12.1 and BA.5 subvariants dominated era
por: Sridhara, Srilekha, et al.
Publicado: (2023)

Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants
por: Qu, Panke, et al.
Publicado: (2022)

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
por: Rössler, Annika, et al.
Publicado: (2022)

Emergence of Omicron BA.2.12.1 in Pakistan: What does it mean for the South Asian nation?
por: Awan, Hashir Ali, et al.
Publicado: (2022)

BA.2.12.1 is a new omicron offshoot that is a highly contagious but not severe disease
por: Beheshti Namdar, Ali, et al.
Publicado: (2022)

Genomic surveillance of SARS-CoV-2 upsurge in India due to Omicron sub-lineages BA.2.74, BA.2.75 and BA.2.76
por: Singh, Urvashi B., et al.
Publicado: (2023)

Structural characteristics of the SARS-CoV-2 Omicron lineages BA.1 and BA.2 virions
por: Ma, Xiaoyu, et al.
Publicado: (2023)

Neutralization of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera
por: Wang, Xun, et al.
Publicado: (2022)

Results of contact tracing for SARS-CoV-2 Omicron sub-lineages (BA.4, BA.5, BA.2.75) and the household secondary attack risk
por: Yu, Mi, et al.
Publicado: (2023)

Hospitalisation and mortality risk of SARS-COV-2 variant omicron sub-lineage BA.2 compared to BA.1 in England
por: Webster, H. H., et al.
Publicado: (2022)

Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa
por: Tegally, Houriiyah, et al.
Publicado: (2022)

Clinical severity of omicron lineage BA.2 infection compared with BA.1 infection in South Africa
por: Wolter, Nicole, et al.
Publicado: (2022)

Omicron BA.5 Neutralization among Vaccine-Boosted Persons with Prior Omicron BA.1/BA.2 Infections
por: Pedersen, Rune M., et al.
Publicado: (2022)

Comparison of SARS-CoV-2 Viral Loads in the Nasal Mucosa of Patients Infected With BA.1, BA.2, or BA.5 Omicron Lineages
por: Tozer, Kyla, et al.
Publicado: (2022)

Clinical severity of SARS-CoV-2 Omicron BA.4 and BA.5 lineages compared to BA.1 and Delta in South Africa
por: Wolter, Nicole, et al.
Publicado: (2022)

Further quantitative in silico analysis of SARS-CoV-2 S-RBD Omicron BA.4, BA.5, BA.2.75, BQ.1, and BQ.1.1 transmissibility
por: Hanai, Toshihiko
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lvtg9jv0e39okuspefi8h24vl1